Global Blood Gas and Electrolyte Analyzers Market to Reach USD 985 Million by 2026
|
By LabMedica International staff writers Posted on 30 Jun 2021 |

Illustration
The global blood gas and electrolyte analyzers market is projected to grow at a CAGR of 5.1% from an estimated USD 728.7 million in 2020 to USD 985 million by 2026, driven by improving infrastructure in diagnostic centers, hospitals and clinical laboratories, and a rise in the integration of critical equipment such as analyzers in ICUs, NICUs, and emergency and trauma units.
These are the latest findings of a new market study published by Global Industry Analysts Inc., (San Jose, CA, USA), a market research company.
Blood gas and electrolyte analyzers are commonly used to test numerous parameters in the blood for identifying drug consumption, diabetes and blood vessel hemorrhage. The growth of the global blood gas and electrolyte analyzers market is being significantly boosted by the rising number of patients in critical care units and intensive care units (ICU); and the increasing demand for integrated, high-throughput systems that measure multiple parameters (such as creatinine, urea, nitrogen) in a short time, which is crucial for emergency situations. Another growth driver for the global market is the increasing adoption of these devices across hospitals, emergency wards and diagnostic centers. The growing relevance of point-of-care diagnosis within the healthcare industry due to its numerous advantages such as bedside care is poised to propel the market demand. Increasing spending on handheld, compact blood gas analyzers offering faster results and addressing needs of critical care services, operation rooms and emergency healthcare services will further boost global demand.
The Portable segment is projected to record a 5.8% CAGR to reach USD 681.6 million in 2026, while the Benchtop segment is expected to grow at a CAGR of 3.8% CAGR over the analysis period. The growing penetration of Point-of-Care (PoC) patient monitoring instruments, coupled with continued innovations and technology improvements taking place in the portable/handheld blood gas analyzers, is encouraging end users to switch over to the PoC version. Benchtop blood gas analyzer, also known as central laboratory analyzer, is generally placed in central laboratories of large hospitals, to undertake high volumes of blood gas testing. Due to the time critical nature of blood gas tests, especially in critical care departments, benchtop analyzers are moving out of the central laboratory and are being placed in near-patient locations in critical care areas such as ICU, CCU, ED, and OR.
Geographically, the US blood gas and electrolyte analyzers market is estimated to be valued at USD 223.1 million in 2021, driven by the demand for sophisticated medical infrastructure and favorable reimbursement plans of consumers in the region. The Chinese market for blood gas and electrolyte analyzers is projected to a record a CAGR of 6.5% over the analysis period to reach USD 111.7 million by 2026. Japan and Canada have been each forecasted to grow at a rate of 4.1% and 4.3%, respectively over the analysis period. Within Europe, Germany is forecasted to grow at a CAGR of approximately 4.7%. The Asia-Pacific market holds high growth potential owing to its vast population, high unmet needs of patients, and higher disposable incomes. The introduction of favorable government initiatives, increasing prevalence of various chronic medical conditions and growing number of new hospitals is also expected to drive the growth of the blood gas and electrolyte analyzers market in Asia-Pacific.
Related Links:
Global Industry Analysts Inc.
These are the latest findings of a new market study published by Global Industry Analysts Inc., (San Jose, CA, USA), a market research company.
Blood gas and electrolyte analyzers are commonly used to test numerous parameters in the blood for identifying drug consumption, diabetes and blood vessel hemorrhage. The growth of the global blood gas and electrolyte analyzers market is being significantly boosted by the rising number of patients in critical care units and intensive care units (ICU); and the increasing demand for integrated, high-throughput systems that measure multiple parameters (such as creatinine, urea, nitrogen) in a short time, which is crucial for emergency situations. Another growth driver for the global market is the increasing adoption of these devices across hospitals, emergency wards and diagnostic centers. The growing relevance of point-of-care diagnosis within the healthcare industry due to its numerous advantages such as bedside care is poised to propel the market demand. Increasing spending on handheld, compact blood gas analyzers offering faster results and addressing needs of critical care services, operation rooms and emergency healthcare services will further boost global demand.
The Portable segment is projected to record a 5.8% CAGR to reach USD 681.6 million in 2026, while the Benchtop segment is expected to grow at a CAGR of 3.8% CAGR over the analysis period. The growing penetration of Point-of-Care (PoC) patient monitoring instruments, coupled with continued innovations and technology improvements taking place in the portable/handheld blood gas analyzers, is encouraging end users to switch over to the PoC version. Benchtop blood gas analyzer, also known as central laboratory analyzer, is generally placed in central laboratories of large hospitals, to undertake high volumes of blood gas testing. Due to the time critical nature of blood gas tests, especially in critical care departments, benchtop analyzers are moving out of the central laboratory and are being placed in near-patient locations in critical care areas such as ICU, CCU, ED, and OR.
Geographically, the US blood gas and electrolyte analyzers market is estimated to be valued at USD 223.1 million in 2021, driven by the demand for sophisticated medical infrastructure and favorable reimbursement plans of consumers in the region. The Chinese market for blood gas and electrolyte analyzers is projected to a record a CAGR of 6.5% over the analysis period to reach USD 111.7 million by 2026. Japan and Canada have been each forecasted to grow at a rate of 4.1% and 4.3%, respectively over the analysis period. Within Europe, Germany is forecasted to grow at a CAGR of approximately 4.7%. The Asia-Pacific market holds high growth potential owing to its vast population, high unmet needs of patients, and higher disposable incomes. The introduction of favorable government initiatives, increasing prevalence of various chronic medical conditions and growing number of new hospitals is also expected to drive the growth of the blood gas and electrolyte analyzers market in Asia-Pacific.
Related Links:
Global Industry Analysts Inc.
Latest Industry News
- Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
- Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
- Integrated DNA Technologies Expands into Clinical Diagnostics
- Co-Diagnostics Agreement Expands Commercial and Distribution Reach in South Asia
- Automated MSI Test Gains IVDR Certification to Guide CRC Therapy
- New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network
- MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
- Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
- Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
- QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
- WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
Channels
Clinical Chemistry
view channel
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read more
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read moreMolecular Diagnostics
view channel
ctDNA MRD Test Identifies Breast Cancer Patients Who May Avoid Surgery
Selecting surgery versus non-surgical management in early-stage breast cancer can be challenging for older patients, who often balance disease control with comorbidities and quality-of-life considerations.... Read more
WGS MCED Assay Demonstrates Rising Sensitivity and High Specificity
Early detection of cancer remains difficult across many tumor types, and current single‑cancer screening modalities leave significant gaps. Blood‑based, multi‑cancer assays aim to detect tumor signals... Read moreHematology
view channel
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read more
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read more
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more







